ArticleBiological psychiatry2026
Kappa Opioid Receptor Availability in Borderline Personality Disorder: An In Vivo Investigation With [
Article in Biological psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundBorderline personality disorder (BPD) is a chronic mental health condition associated with marked elevations in disability. Limited pharmacological treatment options are currently available, and kappa opioid receptors (KORs) have been identified as a promising treatment target. However, the KOR system has not yet been directly examined in BPD. In this study, we examined KORs in individuals with BPD and investigated links between KORs and BPD's clinical features.
methodsTwenty individuals with BPD and 20 demographically matched healthy control (HC) volunteer participants were scanned with [
resultsNo differences in age or sex were observed between HC participants (mean [SD] age = 32.94 [8.45], 60% female) and individuals with BPD (mean [SD] age = 33.30 [9.34], 60% female). In individuals with BPD, KOR V
conclusionsThe findings demonstrate differences in KOR availability in BPD and relationships between KOR availability and clinically relevant features. Results highlight the relevance of KOR in BPD pathophysiology and further implicate the opioid system as a promising target for treatment development in BPD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.